Last $147.27 USD
Change Today +0.63 / 0.43%
Volume 1.4M
PRGO On Other Exchanges
Symbol
Exchange
New York
Tel Aviv
Frankfurt
As of 8:04 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

perrigo co plc (PRGO) Snapshot

Open
$146.46
Previous Close
$146.64
Day High
$147.86
Day Low
$145.96
52 Week High
02/28/14 - $168.39
52 Week Low
09/27/13 - $122.12
Market Cap
19.7B
Average Volume 10 Days
925.2K
EPS TTM
$3.86
Shares Outstanding
133.8M
EX-Date
08/27/14
P/E TM
38.2x
Dividend
$0.42
Dividend Yield
0.27%
Current Stock Chart for PERRIGO CO PLC (PRGO)

perrigo co plc (PRGO) Details

Perrigo Company plc, through its subsidiaries, develops, manufactures, and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API). Its Consumer Healthcare segment offers OTC pharmaceutical products in the areas of analgesics, cough/cold/allergy/sinus, gastrointestinal, smoking cessation, and animal health products, as well as in the areas of feminine hygiene, diabetes care, and dermatological care; and contract manufacturing services. The company’s Nutritionals segment offers infant and toddler formula products, infant and toddler foods, as well as vitamins, minerals, and dietary supplement products to retailers, distributors, and consumers. Its Rx Pharmaceuticals segment develops, manufactures and markets a portfolio of Rx drugs in topical dosage forms, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, and powders, as well as controlled substances, injectables, hormones, oral solid dosage forms, and oral liquid formulations. This segment provides its products to chain drug stores, wholesalers, distributors, hospital systems, and group purchasing organizations. The company’s API segment develops, manufactures, and markets API that are used in the production of pharmaceutical products to generic drug industries and branded pharmaceutical companies. Its Specialty Sciences segment provides Tysabri, which is used for the treatment of Multiple Sclerosis; and Prialt, a non-narcotic intrathecal analgesic. The company also offers pharmaceutical and medical diagnostic products. The company offers its products primarily in the United States, the United Kingdom, Mexico, Israel, and Australia, as well as in Canada, China, and Latin America. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

10,220 Employees
Last Reported Date: 08/14/14
Founded in 1887

perrigo co plc (PRGO) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.1M
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $526.3K
Executive Vice President of Global Operations...
Total Annual Compensation: $452.5K
Executive Vice President, General Counsel and...
Total Annual Compensation: $452.5K
Executive Vice President and General Manager ...
Total Annual Compensation: $441.0K
Compensation as of Fiscal Year 2013.

perrigo co plc (PRGO) Key Developments

Omega Pharma Attracts Interest

Omega Pharma NV has attracted interest from companies includingPerrigo Company Public Limited Company (NYSE:PRGO) and Boehringer Ingelheim GmbH, according to people familiar with the matter. Bayer AG (DB:BAYN) and Sanofi (ENXTPA:SAN)may also join other bidders. The sale, which is still in early stages, could fetch more than €4 billion, the people said. Omega Pharma is working with Morgan Stanley, Bloomberg News reported in August.

Perrigo Company Public Limited Company Presents at CRT Capital Group's 2nd Annual Investor Conference, Sep-16-2014

Perrigo Company Public Limited Company Presents at CRT Capital Group's 2nd Annual Investor Conference, Sep-16-2014 . Venue: Delamar Hotel, Greenwich, Connecticut, United States.

Perrigo Company Public Limited Company Reports Un-Audited Consolidated Earnings Results for the Fourth Quarter and Year Ended June 28, 2014; Provides Earnings Guidance for the Fiscal Year 2015

Perrigo Company Public Limited Company reported un-audited consolidated earnings results for the fourth quarter and year ended June 28, 2014. For the year, the company’s sales increased 15% year-over-year to a record $4.06 billion compared to $3.6 billion in last year. Adjusted net income increased 40% to $739.5 million or $6.39 per diluted share compared to $529.7 million or $5.61 per diluted share, GAAP net income was $205.3 million, or $1.77 per diluted share, includes amortization expense and other charges compared to $441.9 million or $4.68 per diluted share, operating income was $567.0 million compared to $679.1 million, income from continuing operations before income taxes was $272.6 million compared to $607.7 million, income from continuing was $205.3 million or $1.77 per diluted share compared to $441.9 million or $4.68 per diluted share, net cash from operating activities was $693.5 million compared to $553.8 million and additions to property and equipment was $171.6 million compared to $104.1 million for the last year. Non-GAAP operating income was $1,029.2 million compared to $805.3 million and non-GAAP income before income taxes was $932.1 million compared to $738.6 for the last year. For the quarter, the company reported net sales of $1.1 billion compared to $0.97 billion in last year. Adjusted net income was $234.1 million or $1.74 per diluted share compared to $148.1 million or $1.57 per diluted share, GAAP net income was $131.7 million, or $0.98 per diluted share compared to $118.5 million or $1.25 per diluted share, operating income was $197.4 million compared to $180.1 million, income before income taxes was $165.5 million compared to $161.4 million for the last year. Non-GAAP operating income was $324.6 million compared to $225.2 million and non-GAAP income before income taxes was $296.2 million compared to $206.6 for the last year. Management expects full-year fiscal 2015 adjusted earnings range of $7.20 to $7.50 per diluted share, an increase of 13% to 17% over fiscal 2014 adjusted earnings per share, and reported earnings of between $4.05 and $4.35 per diluted share.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRGO:US $147.27 USD +0.63

PRGO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Endo International PLC $67.70 USD +0.76
Hospira Inc $53.85 USD +0.34
Mallinckrodt PLC $88.82 USD +1.12
Mead Johnson Nutrition Co $97.46 USD -0.48
Mylan Inc/PA $47.36 USD -1.07
View Industry Companies
 

Industry Analysis

PRGO

Industry Average

Valuation PRGO Industry Range
Price/Earnings 82.9x
Price/Sales 4.9x
Price/Book 2.3x
Price/Cash Flow 96.0x
TEV/Sales 3.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PERRIGO CO PLC, please visit www.perrigo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.